TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01406145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0777
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT02211534

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Electromagnetic Field Device
Description: The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
Study: NCT03786796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
Study: NCT03426865

Intervention type: DRUG
Intervention: Axumin PET scan
Description: PET scan prior to RPLND
Study: NCT03377790

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VP-102 - Cantharidin, Topical Film Forming Solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo -Topical Film Forming Solution without VP-102
Description: Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
Study: NCT01515904

Intervention type: BEHAVIORAL
Intervention: STOMP Clinic
Description: A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions.
Study: NCT02770508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir/ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine-tenofovir(FTC/TDF)
Study: NCT01216891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-element, team-oriented treatment
Description: Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
Study: NCT03717662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine gum or nicotine patch
Description: The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
Study: NCT00597714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Stem Cell Transplantation
Description: The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Stem Cell Transplantation
Description: The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
Study: NCT00902941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect 1mg
Description: 1 mg daily orally for 120 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg daily orally for 120 days
Study: NCT03375580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TLC
Description: transform life custom (TLC)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TLC
Description: transform life custom (TLC)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TLC
Description: transform life custom (TLC)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TLC
Description: transform life custom (TLC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 0.5g metformin group，PO tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Zhenzhu Tiaozhi capsule
Description: Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 20mg simvastatin, PO qn
Study: NCT02486549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular Block
Description: Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20ml 0.25% bupivacaine will be injected for brachial plexus block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20ml 0.25% bupivacaine will be injected for brachial plexus block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The Ultrasound will be used for brachial plexus visualization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The Ultrasound will be used for brachial plexus visualization
Study: NCT01754454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Derived MSC
Description: 1×10\^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
Study: NCT01127906

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04531083 100mg
Description: Oral PF-04531083 100mg suspension single dose
Study: NCT04074746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD30/CD16A Monoclonal Antibody AFM13
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Lymphocyte Therapy
Description: Given AFM13-NK cells IV
Study: NCT03475121

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Chemotherapy plus Intrathecal Topotecan
Description: Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Higher Dose Combination Chemotherapy plus Intrathecal Topotecan
Description: GALOP I-based systemic adjuvant therapy plus intrathecal topotecan

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy
Description: GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Adjuvant Therapy
Description: Patients will not receive any adjuvant therapy after enucleation of the affected eye.
Study: NCT03454828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: obese carbohydrate diet
Description: The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lean carbohydrate diet
Description: The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and \<10% of total kcals in the form of sugar).
Study: NCT02952131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Closed Syringe Harvesting Autologous Subdermal Fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AD-cSVF
Description: Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline IV
Description: Normal Saline IV containing AD-cSVF
Study: NCT04274504

Intervention type: DIAGNOSTIC_TEST
Intervention: Osteopontin
Description: Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
Study: NCT01127906

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04531083 2000mg
Description: Oral PF-04531083 2000mg suspension single dose
Study: NCT02368379

Intervention type: OTHER
Group type: OTHER
Intervention: Low dose (1 mcg) ACTH stimulation test
Description: Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.

Intervention type: OTHER
Group type: OTHER
Intervention: Overnight metyrapone test
Description: Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
Study: NCT02772874

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05531578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)
Description: Transfemoral implantation of the INOVARE® transcatheter valve
Study: NCT02375490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Start
Description: Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
Study: NCT04178824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discount Intervention
Description: 15% or 30% discount on fruits and vegetables

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discount Intervention
Description: 15% or 30% discount on fruits and vegetables
Study: NCT02855229

Intervention type: DRUG
Intervention: Methylphenidate
Description: cross-over, single-dose intervention
Study: NCT03535740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib Tablets
Study: NCT04984863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically controlled capsule endoscopy
Description: Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
Study: NCT01660347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of therapy complications
Description: Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
Study: NCT00655707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Expanded CD34+ Haemopoietic cells
Description: Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells
Study: NCT01348308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc (Celsentri)
Description: Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks.
Study: NCT04413552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-2000
Description: INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-2000
Description: INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
Study: NCT01876784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vandetanib (SAR390530)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib (SAR390530)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00004875

Intervention type: DRUG
Intervention: enoxaparin

Intervention type: DRUG
Intervention: heparin
Study: NCT01564888

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ulnar artery compression
Description: Compression of ulnar artery for 2 hours with radial artery hemostasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar artery compression
Description: Compression of ulnar artery for 2 hours with radial artery hemostasis
Study: NCT02267772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Morphine
Description: IV Morphine
Study: NCT02698202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis
Description: twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
Study: NCT04695574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Some clinical evaluation performance tests together with procedure of Closed Kinetic Chain Lower Extremity Stability Test
Description: Clinical evaluation methods
Study: NCT00880230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scuba Iliac Stent System
Description: The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
Study: NCT03430895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab and tremelimumab
Description: Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
Study: NCT01803503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 7 days of sunitinib 12.5mg orally daily during each cycle
Study: NCT04441840

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Probiotic Culture
Description: Both conditions matched in appearance and serving size
Study: NCT01127906

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo suspension
Description: Oral Placebo suspension (matched to PF-04531083 suspension)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo tablet
Description: Oral Placebo tablet (matched to Oxycodone)

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone 20mg
Description: Oral Oxycodone 20mg (Oxycontin) controlled release formulation
Study: NCT02440594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced BHL Program Services
Description: Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced BHL Program Services
Description: Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced BHL Program Services
Description: Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced BHL Program Services
Description: Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BHL Program Services
Description: Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BHL Program Services
Description: Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BHL Program Services
Description: Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BHL Program Services
Description: Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
Study: NCT03810313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Solution for injection (intravitreal use)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Solution for injection (Intravitreal use)
Study: NCT04441840

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inactive Probiotic Culture
Description: Both conditions matched in appearance and serving size
Study: NCT04250532

Intervention type: OTHER
Intervention: Drowning
Description: Measurement of pulse oximetry, after lifeguard immersion during their morning training
Study: NCT00059605

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DOTAP:Chol-fus1
Description: Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.